Neurodyn Inc. acquires Memogain for Dementia in Alzheimer’s Disease

11-Sep-2013 - Germany

Neurodyn Inc. announced that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer’s prescription drug candidate – Memogain®.  Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013.  The terms of the acquisition were not disclosed.

“We are very pleased to complete this acquisition.  Memogain® is a significant improvement over existing Alzheimer’s drugs, and is staged for immediate entry into clinical trials.  It has the potential to follow a fast-track regulatory pathway in both the US and Europe.” said Kenneth Cawkell, Neurodyn CEO.

Memogain® is a patented improvement on the generic drug, galantamine, (Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine).  Galantamine, a plant-derived compound, is widely prescribed to enhance cognition for the treatment of mild to moderateAlzheimer’s disease, but has a limited capacity for brain penetration and significant side effects that limit its effectiveness. Memogain® was developed to have a much higher bioavailability in the brain, without the negative gastro-intestinal side effects that limit patient acceptance.

Neurodyn will also investigate the potential for Memogain® to decrease the amyloid plaque burden associated with Alzheimer’s disease and to induce new cell growth in regions of the brain affected by the disease.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances